← Eichor
Study identifier: NCT06746610 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes

Condition: Monogenic Diabetes  ·  Sponsor: Tianjin Medical University General Hospital

PhaseNA
Planned participants2000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to establish a registry, screening, and individualized management platform for patients with monogenic diabetes mellitus(MDM) using internet-based and mobile application software. The main questions it aims to answer are: * What are the genetic mutations causing MDM in China (genetic landscape)? * How effective and safe is the individualized, molecular-diagnosis-based management platform for MDM in improving patient outcomes? Participants will: * Register in the MDM platform via mobile app or internet-based software * Undergo genetic screening for MDM diagnosis * Participate in follow-up visits for individualized management and monitoring of blood glucose control and outcomes

This description comes directly from the study's public registry record.

Talk to the study team

Ming Liu  ·  +86 183 2201 7516  ·  mingliu@tmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Tianjin Medical University General HospitalTianjin, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06746610